{"id":333,"date":"2026-04-06T19:05:54","date_gmt":"2026-04-06T19:05:54","guid":{"rendered":"https:\/\/depcell.com\/?page_id=333"},"modified":"2026-04-06T19:57:44","modified_gmt":"2026-04-06T19:57:44","slug":"anti-aging-and-stem-cells","status":"publish","type":"page","link":"https:\/\/depcell.com\/lv\/anti-aging-and-stem-cells\/","title":{"rendered":"Pret-noveco\u0161an\u0101s un cilmes \u0161\u016bnas"},"content":{"rendered":"\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n
\n
\n

The modern anti-aging conversation is no longer limited to cosmetics or lifestyle hacks. It increasingly focuses on healthspan: the part of life in which a person can think clearly, move independently, heal efficiently, and remain free from prolonged disability. That helps explain why wealthy public figures and large investors are paying such close attention. Entrepreneur Bryan Johnson has publicly pursued a highly expensive personal longevity programme, while companies such as Altos Labs explicitly frame cell rejuvenation as a route toward reversing disease, injury, and disability throughout life [14,15]. For some people, longer healthspan is also a way to preserve the years in which they can lead, create, invest, and continue building wealth. The celebrity angle attracts headlines, but the deeper scientific question is more important: can we keep the body\u2019s repair system biologically younger for longer?
Aging is often described as \u201cwear and tear,\u201d but the biology is more precise than that. In the updated hallmarks of aging, stem-cell exhaustion and chronic inflammation are recognised as central features of the aging process [1]. This matters because tissues do not maintain themselves by magic. They rely on specialised repair and support cells, including stem and stromal-cell populations, to replace damage, regulate inflammation, and maintain healthy microenvironments. As these populations age, they usually proliferate less efficiently, migrate less effectively, and release a more disturbed, sometimes more inflammatory set of signals [2,3]. In practical terms, the body can still try to heal, but the healing crew becomes smaller, slower, and less reliable.
From an anti-aging perspective, cell source is crucial. Umbilical-cord-derived material, especially Wharton\u2019s jelly, is widely discussed as a comparatively youthful source of mesenchymal stromal cells, with strong proliferative capacity and favourable immunomodulatory features [4]. Adult adipose tissue, by contrast, is attractive because it is accessible and autologous: the cells come from the patient\u2019s own body, which may simplify matching and logistics [5]. These two sources therefore serve different purposes. Cord-derived cells represent a \u201cyoung reserve.\u201d Adipose-derived cells represent a practical personal reserve. DEPCELL\u2019s vision sits precisely at this interface: use intelligent selection to make both sources more useful, instead of assuming that every cell in every sample has equal value.
A tissue sample is not a uniform army of ideal cells. It is a mixed population. Some cells are young and resilient. Some are old and tired. Some still look acceptable under routine observation but are already drifting toward senescence or poor function. Some material is simply debris. This is why \u201cmore cells\u201d does not automatically mean \u201cbetter therapy.\u201d In regenerative medicine, a smarter approach is to identify the fraction that still carries the strongest repair potential. That principle becomes even more important in aging, because a tired organism is unlikely to benefit fully from a tired repair-cell population. The goal is not to collect the largest crowd. It is to enrich the most useful part of the crowd.
This is where dielectrophoresis becomes interesting. In simple terms, dielectrophoresis uses a non-uniform electric field to move cells according to their dielectric behaviour. Because membranes, cytoplasm, internal structure, and water content differ from one cell state to another, cells do not respond identically [9,10]. Importantly, these electrical differences can reflect biology that is not yet obvious under a microscope. Studies have shown that stem cells and their differentiated progeny have distinct dielectric signatures, that early differentiation can alter dielectrophoretic behaviour before classic morphology fully changes, and that aged human mesenchymal stem cells can display characteristic electrical phenotypes as they expand in culture [9,11,12]. More recently, label-free insulating dielectrophoresis has been used to sort human mesenchymal stem-cell subpopulations directly [13].
For therapeutic use, gentleness matters. Many standard laboratory workflows are excellent for analysis but less ideal when the final aim is to keep fragile living cells functional. A dielectrophoresis-style strategy is attractive because it can work without fluorescent labels and can focus on a cell\u2019s behaviour rather than on a destructive endpoint. That does not make every DEP system automatically clinical, and it certainly does not remove the need for validation. But it does point toward a future in which cell selection is based on functionally meaningful physical properties instead of rough appearance alone. That is the logic behind DEPCELL\u2019s direction: a platform intended to enrich the more functional fraction of cord-derived or adipose-derived cell populations while preserving their usefulness for downstream regenerative applications.
A second practical question is timing. In principle, selected cells or source materials can follow two broad paths: a near-term treatment pathway or a biobank pathway. Cryopreservation keeps future options open, and both cord-blood products and adipose-derived materials have supporting evidence for long-term preservation strategies [6,7]. A 2024 study from the Jose Carreras Cord Blood Bank reported meaningful quality data even after very long storage intervals, while systematic-review evidence supports viable cryopreservation approaches for adipose tissues and adipose-derived cells [6,7]. Biobanking is not a guarantee that any desired future indication will be approved or effective. But it does preserve optionality. For families storing cord-derived material, or adults storing carefully selected autologous material, that optionality may matter for healthier aging, later reconstruction, or future rescue strategies in high-burden medical situations.
oday, high-end longevity medicine often looks like a luxury market. A small number of wealthy people can afford intensive monitoring, bespoke interventions, and experimental cell procedures. Public discussion sometimes makes this field sound as if healthier aging will be reserved for billionaires. That should not be the endpoint. A more socially useful future would make regenerative tools more precise, more regulated, and more affordable. If selection technology can enrich better cells instead of wasting mixed and low-quality material, it may help lower inefficiency and improve consistency. That does not eliminate the need for trials, manufacturing controls, or careful regulation. In fact, the opposite is true: the EMA has explicitly warned that unregulated advanced-therapy products can pose serious risks to patients [16]. The task is therefore not to sell fantasies of immortality, but to build safer and more accessible routes toward longer healthspan.
A realistic anti-aging strategy is not about living forever. It is about reducing the number of years dominated by frailty, inflammation, pain, and irreversible loss of function. Stem cells are relevant to that goal because they sit close to the body\u2019s repair machinery. But the scientific frontier is moving from a simple question \u2014 \u201cDo we have stem cells?\u201d \u2014 to a harder and more useful one: \u201cWhich cells are still strong, resilient, and worth keeping?\u201d If DEPCELL and related approaches can answer that question well, then anti-aging medicine may shift from a luxury story about a few rich people to a more practical story about preserving function for many more patients.<\/p>\n\n\n\n

Selected references:<\/strong><\/p>\n\n\n\n

    \n
  • 1. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278. doi:10.1016\/j.cell.2022.11.001.<\/li>\n\n\n\n
  • 2. Lee BC, Yu KR. Impact of mesenchymal stem cell senescence on inflammaging. BMB Rep. 2020;53(2):65-73. doi:10.5483\/BMBRep.2020.53.2.291.<\/li>\n\n\n\n
  • 3. Yang X, Wang Y, Rovella V, Candi E, Jia W, Bernassola F, et al. Aged mesenchymal stem cells and inflammation: from pathology to potential therapeutic strategies. Biol Direct. 2023;18(1):40. doi:10.1186\/s13062-023-00394-6.<\/li>\n\n\n\n
  • 4. Kalaszczynska I, Ferdyn K. Wharton\u2019s jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance. Biomed Res Int. 2015;2015:430847. doi:10.1155\/2015\/430847.<\/li>\n\n\n\n
  • 5. Frese L, Dijkman PE, Hoerstrup SP. Adipose tissue-derived stem cells in regenerative medicine. Transfus Med Hemother. 2016;43(4):268-274. doi:10.1159\/000448180.<\/li>\n\n\n\n
  • 6. Crowley CA, Smith WPW, Seah KTM, Lim S-K, Khan WS. Cryopreservation of human adipose tissues and adipose-derived stem cells with DMSO and\/or trehalose: A systematic review. Cells. 2021;10(7):1837. doi:10.3390\/cells10071837.<\/li>\n\n\n\n
  • 7. Liedtke S, et al. Long-Term Stability of Cord Blood Units After 29 Years of Cryopreservation: Follow-Up Data From the Jose Carreras Cord Blood Bank. Stem Cells Transl Med. 2024;13(1):30-42. doi:10.1093\/stcltm\/szad071.<\/li>\n\n\n\n
  • 8. Huang Y, Wu Q, Tam PKH. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. Int J Mol Sci. 2022;23(17):10023. doi:10.3390\/ijms231710023.<\/li>\n\n\n\n
  • 9. Flanagan LA, Lu J, Wang L, Marchenko SA, Jeon NL, Lee AP, Monuki ES. Unique dielectric properties distinguish stem cells and their differentiated progeny. Stem Cells. 2008;26(3):656-665. doi:10.1634\/stemcells.2007-0810.<\/li>\n\n\n\n
  • 10. Giduthuri AT, Theodossiou SK, Schiele NR, Srivastava SK. Dielectrophoresis as a tool for electrophysiological characterization of stem cells. Biophys Rev. 2020;1(1):011304. doi:10.1063\/5.0025056.<\/li>\n\n\n\n
  • 11. Tivig IC, Vallet L, Moisescu MG, Fernandes R, Mir LM, Tudor S. Early differentiation of mesenchymal stem cells is reflected in their dielectrophoretic behavior. Sci Rep. 2024;14(1):4330. doi:10.1038\/s41598-024-54350-z.<\/li>\n\n\n\n
  • 12. Simpkins LLC, Tsai T, Egun E, Adams TNG. Electrical phenotyping of aged human mesenchymal stem cells using dielectrophoresis. Micromachines. 2025;16(4):435. doi:10.3390\/mi16040435.<\/li>\n\n\n\n
  • 13. Rashad ZA, Lacy KL, Egun E, Moore JS, Adams TNG. Label-Free Sorting of Human Mesenchymal Stem Cells Using Insulating Dielectrophoresis. Electrophoresis. 2025;46(18):e70001. doi:10.1002\/elps.70001.<\/li>\n\n\n\n
  • 14. Altos Labs. Our mission is to restore cell health and resilience through cell rejuvenation to reverse disease, injury and the disabilities that can occur throughout life. Available from: https:\/\/www.altoslabs.com\/ (accessed 2026-04-06).<\/li>\n\n\n\n
  • 15. Vance A. How to Be 18 Years Old Again for Only $2 Million a Year. Bloomberg Businessweek. 2023 Jan 25. Available from: https:\/\/www.bloomberg.com\/news\/features\/2023-01-25\/anti-aging-techniques-taken-to-extreme-by-bryan-johnson (accessed 2026-04-06).<\/li>\n\n\n\n
  • 16. European Medicines Agency. Unregulated advanced therapy medicinal products pose serious risks to health. 2025 Mar 13. Available from: https:\/\/www.ema.europa.eu\/en\/news\/unregulated-advanced-therapy-medicinal-products-pose-serious-risks-health (accessed 2026-04-06).<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    The modern anti-aging conversation is no longer limited to cosmetics or lifestyle hacks. It increasingly focuses on healthspan: the part of life in which a person can think clearly, move independently, heal efficiently, and remain free from prolonged disability. That helps explain why wealthy public figures and large investors are paying such close attention. Entrepreneur […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-with-title","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-333","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/depcell.com\/lv\/wp-json\/wp\/v2\/pages\/333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depcell.com\/lv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/depcell.com\/lv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/depcell.com\/lv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/depcell.com\/lv\/wp-json\/wp\/v2\/comments?post=333"}],"version-history":[{"count":4,"href":"https:\/\/depcell.com\/lv\/wp-json\/wp\/v2\/pages\/333\/revisions"}],"predecessor-version":[{"id":352,"href":"https:\/\/depcell.com\/lv\/wp-json\/wp\/v2\/pages\/333\/revisions\/352"}],"wp:attachment":[{"href":"https:\/\/depcell.com\/lv\/wp-json\/wp\/v2\/media?parent=333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}